In prostate cancer, AR signaling in stromal cells, initially high during prostate development, progressively decreases as cancer advances, correlating with worse clinical outcomes and a shift from androgen-dependent paracrine to autocrine pathways in cancer cells. Here, AR is linked to prostate carcinoma.